{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T20:13:24Z","timestamp":1792872804543,"version":"4.5.0"},"reference-count":99,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008741","name":"European Alliance of Associations for Rheumatology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008741","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ard.2026.06.009","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T11:34:21Z","timestamp":1784633661000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["2025 EULAR recommendations for the management of polymyalgia rheumatica and primary large vessel vasculitis"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9771-6667","authenticated-orcid":false,"given":"Chetan B.","family":"Mukhtyar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Nikiphorou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8242-6798","authenticated-orcid":false,"given":"Alice","family":"Bartoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6858-4338","authenticated-orcid":false,"given":"Mrinalini","family":"Dey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9822-0604","authenticated-orcid":false,"given":"Georgina","family":"Ducker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5035-7396","authenticated-orcid":false,"given":"Durga P.","family":"Misra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Monti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8895-6941","authenticated-orcid":false,"given":"Paul","family":"Studenic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7831-921X","authenticated-orcid":false,"given":"Alvise","family":"Berti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9783-1780","authenticated-orcid":false,"given":"Daniel","family":"Blockmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5652-4423","authenticated-orcid":false,"given":"Elisabeth","family":"Brouwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2534-550X","authenticated-orcid":false,"given":"Frank","family":"Buttgereit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Cannings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4730-0938","authenticated-orcid":false,"given":"Maria C.","family":"Cid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2538-3362","authenticated-orcid":false,"given":"Richard","family":"Conway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Christ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0173-0668","authenticated-orcid":false,"given":"Christian","family":"Dejaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2474-3389","authenticated-orcid":false,"given":"Kresten K.","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7358-2051","authenticated-orcid":false,"given":"Lisa","family":"Kingham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9284-7345","authenticated-orcid":false,"given":"Peter A.","family":"Merkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7169-6936","authenticated-orcid":false,"given":"Aladdin J.","family":"Mohammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6314-4437","authenticated-orcid":false,"given":"Susan P.","family":"Mollan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6291-157X","authenticated-orcid":false,"given":"Berit D.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3989-1192","authenticated-orcid":false,"given":"Cristina","family":"Ponte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3628-9996","authenticated-orcid":false,"given":"David","family":"Saadoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7831-8738","authenticated-orcid":false,"given":"Wolfgang A.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7708-2487","authenticated-orcid":false,"given":"Kenneth J.","family":"Warrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8014-1801","authenticated-orcid":false,"given":"Bernhard","family":"Hellmich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ard.2026.06.009_bib0001","first-page":"1739","article-title":"The incidence of polymyalgia rheumatica and temporal arteritis in the county of Aust Agder, south Norway: a prospective study 1987-94","volume":"24","author":"Gran","year":"1997","journal-title":"J Rheumatol."},{"issue":"11","key":"10.1016\/j.ard.2026.06.009_bib0002","doi-asserted-by":"crossref","first-page":"5818","DOI":"10.1093\/rheumatology\/keaf367","article-title":"Frequency, diagnosis, and management of polymyalgia rheumatica in Germany-database analysis of medical insurance data","volume":"64","author":"Schmidt","year":"2025","journal-title":"Rheumatology (Oxford)."},{"issue":"10","key":"10.1016\/j.ard.2026.06.009_bib0003","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1136\/ard-2023-224191","article-title":"Incidence of primary large vessel vasculitis in Norfolk, UK from 2011 to 2020","volume":"82","author":"Mukhtyar","year":"2023","journal-title":"Ann Rheum Dis."},{"issue":"5","key":"10.1016\/j.ard.2026.06.009_bib0004","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.semarthrit.2020.07.005","article-title":"Incidence and prevalence of giant cell arteritis and polymyalgia rheumatica: A systematic literature review","volume":"50","author":"Sharma","year":"2020","journal-title":"Semin Arthritis Rheum."},{"issue":"11","key":"10.1016\/j.ard.2026.06.009_bib0005","doi-asserted-by":"crossref","first-page":"4982","DOI":"10.1093\/rheumatology\/keab406","article-title":"A systematic review and meta-analysis of the incidence rate of Takayasu arteritis","volume":"60","author":"Rutter","year":"2021","journal-title":"Rheumatology (Oxford)."},{"issue":"3","key":"10.1016\/j.ard.2026.06.009_bib0006","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1136\/ard.2008.088351","article-title":"EULAR recommendations for the management of large vessel vasculitis","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann Rheum Dis."},{"issue":"10","key":"10.1016\/j.ard.2026.06.009_bib0007","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1136\/annrheumdis-2015-207492","article-title":"2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism\/American College of Rheumatology collaborative initiative","volume":"74","author":"Dejaco","year":"2015","journal-title":"Ann Rheum Dis."},{"issue":"1","key":"10.1016\/j.ard.2026.06.009_bib0008","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","article-title":"2018 Update of the EULAR recommendations for the management of large vessel vasculitis","volume":"79","author":"Hellmich","year":"2020","journal-title":"Ann Rheum Dis."},{"issue":"10","key":"10.1016\/j.ard.2026.06.009_bib0009","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s11926-020-00948-x","article-title":"Pathogenesis of Giant Cell Arteritis and Takayasu Arteritis-Similarities and Differences","volume":"22","author":"Watanabe","year":"2020","journal-title":"Curr Rheumatol Rep."},{"issue":"Suppl 1","key":"10.1016\/j.ard.2026.06.009_bib0010","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/1756-185X.13288","article-title":"Takayasu arteritis and giant cell arteritis: are they a spectrum of the same disease?","volume":"22","author":"Kermani","year":"2019","journal-title":"Int J Rheum Dis."},{"issue":"7330","key":"10.1016\/j.ard.2026.06.009_bib0011","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0140-6736(64)92784-9","article-title":"Arteritis in \"polymyalgia rheumatica\"","volume":"1","author":"Hamrin","year":"1964","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.ard.2026.06.009_bib0012","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/s41584-023-00976-8","article-title":"Disease stratification in GCA and PMR: state of the art and future perspectives","volume":"19","author":"Tomelleri","year":"2023","journal-title":"Nat Rev Rheumatol."},{"issue":"1","key":"10.1016\/j.ard.2026.06.009_bib0013","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1136\/annrheumdis-2014-206350","article-title":"2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations","volume":"74","author":"van der Heijde","year":"2015","journal-title":"Ann Rheum Dis."},{"issue":"10","key":"10.1016\/j.ard.2026.06.009_bib0014","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1136\/annrheumdis-2015-207578","volume":"74","author":"Dejaco","year":"2015","journal-title":"Ann Rheum Dis."},{"issue":"2","key":"10.1016\/j.ard.2026.06.009_bib0015","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001003","article-title":"Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis","volume":"5","author":"Monti","year":"2019","journal-title":"RMD Open."},{"issue":"2","key":"10.1016\/j.ard.2026.06.009_bib0016","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001020","article-title":"Management of Takayasu arteritis: a systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis","volume":"5","author":"Agueda","year":"2019","journal-title":"RMD Open."},{"key":"10.1016\/j.ard.2026.06.009_bib0017","article-title":"Systematic literature review informing the 2025 EULAR recommendation for the management of polymyalgia rheumatica and large vessel vasculitis: focus on referral and diagnosis","author":"Bartoletti","year":"2026","journal-title":"EULAR Rheumatology Open."},{"key":"10.1016\/j.ard.2026.06.009_bib0018","article-title":"A systematic literature review to inform the 2025 EULAR recommendations for management of Polymyalgia Rheumatica and Large Vessel Vasculitis: management of disease including relapse and complications","author":"Dey","year":"2026","journal-title":"EULAR Rheumatology Open."},{"issue":"2","key":"10.1016\/j.ard.2026.06.009_bib0019","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3899\/jrheum.121306","article-title":"Updated method guidelines for cochrane musculoskeletal group systematic reviews and metaanalyses","volume":"41","author":"Ghogomu","year":"2014","journal-title":"J Rheumatol."},{"key":"10.1016\/j.ard.2026.06.009_bib0020","series-title":"The philosophy of evidence-based medicine","first-page":"229","author":"Howick","year":"2011"},{"issue":"6","key":"10.1016\/j.ard.2026.06.009_bib0021","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1136\/annrheumdis-2021-221733","article-title":"EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome","volume":"81","author":"Drosos","year":"2022","journal-title":"Ann Rheum Dis."},{"issue":"8","key":"10.1016\/j.ard.2026.06.009_bib0022","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1136\/ard-2023-223895","article-title":"Age at diagnosis influences the clinical phenotype, treatment strategies and outcomes in patients with giant cell arteritis: results from the observational GCAGE study on a large cohort of 1004 patients","volume":"82","author":"Monti","year":"2023","journal-title":"Ann Rheum Dis."},{"issue":"6","key":"10.1016\/j.ard.2026.06.009_bib0023","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1093\/rheumatology\/keaf051","article-title":"Cerebrovascular accidents in giant cell arteritis: prevalence and predictive factors from the ARTESER registry","volume":"64","author":"Martin-Gutierrez","year":"2025","journal-title":"Rheumatology (Oxford)."},{"issue":"3","key":"10.1016\/j.ard.2026.06.009_bib0024","doi-asserted-by":"crossref","first-page":"206","DOI":"10.7861\/clinmed.2022-0415","article-title":"Frequency of visual involvement in a 10-year interdisciplinary cohort of patients with giant cell arteritis","volume":"23","author":"Smith","year":"2023","journal-title":"Clin Med (Lond)."},{"issue":"6","key":"10.1016\/j.ard.2026.06.009_bib0025","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1093\/rheumatology\/keab179","article-title":"Ultrasonography in the diagnosis and follow-up of giant cell arteritis","volume":"60","author":"Coath","year":"2021","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.ard.2026.06.009_bib0026","article-title":"Fast-Track Ultrasound Clinic for the Diagnosis of Giant Cell Arteritis Changes the Prognosis of the Disease but Not the Risk of Future Relapse","volume":"7","author":"Monti","year":"2020","journal-title":"Front Med (Lausanne)."},{"issue":"6","key":"10.1016\/j.ard.2026.06.009_bib0027","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1136\/ard-2023-224543","article-title":"EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice: 2023 update","volume":"83","author":"Dejaco","year":"2024","journal-title":"Ann Rheum Dis."},{"issue":"11","key":"10.1016\/j.ard.2026.06.009_bib0028","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1136\/ard-2023-225134","article-title":"Recommendations for early referral of individuals with suspected polymyalgia rheumatica: an initiative from the international giant cell arteritis and polymyalgia rheumatica study group","volume":"83","author":"Keller","year":"2024","journal-title":"Ann Rheum Dis."},{"issue":"8","key":"10.1016\/j.ard.2026.06.009_bib0029","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1093\/rheumatology\/keac713","article-title":"An international survey of current management practices for polymyalgia rheumatica by general practitioners and rheumatologists","volume":"62","author":"Donskov","year":"2023","journal-title":"Rheumatology (Oxford)."},{"issue":"676","key":"10.1016\/j.ard.2026.06.009_bib0030","doi-asserted-by":"crossref","first-page":"e783","DOI":"10.3399\/bjgp18X699557","article-title":"Challenges of diagnosing and managing polymyalgia rheumatica: a multi-methods study in UK general practice","volume":"68","author":"Helliwell","year":"2018","journal-title":"Br J Gen Pract."},{"issue":"1","key":"10.1016\/j.ard.2026.06.009_bib0031","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/rheumatology\/kead189","article-title":"Prevalence and characteristics of subclinical giant cell arteritis in polymyalgia rheumatica","volume":"63","author":"De Miguel","year":"2024","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.ard.2026.06.009_bib0032","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X221149963","article-title":"Prevalence and characteristics of giant cell arteritis in patients with newly diagnosed polymyalgia rheumatica - a prospective cohort study","volume":"15","author":"Burg","year":"2023","journal-title":"Ther Adv Musculoskelet Dis."},{"issue":"3","key":"10.1016\/j.ard.2026.06.009_bib0033","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/ard-2023-224768","article-title":"Subclinical giant cell arteritis increases the risk of relapse in polymyalgia rheumatica","volume":"83","author":"De Miguel","year":"2024","journal-title":"Ann Rheum Dis."},{"issue":"8","key":"10.1016\/j.ard.2026.06.009_bib0034","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1136\/ard.61.8.718","article-title":"Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology","volume":"61","author":"Buttgereit","year":"2002","journal-title":"Ann Rheum Dis."},{"issue":"8","key":"10.1016\/j.ard.2026.06.009_bib0035","doi-asserted-by":"crossref","first-page":"4756","DOI":"10.1093\/rheumatology\/keaf170","article-title":"The effect of prednisolone initiation and short-term discontinuation on the clinical assessment of polymyalgia rheumatica","volume":"64","author":"Vaben","year":"2025","journal-title":"Rheumatology (Oxford)."},{"issue":"9","key":"10.1016\/j.ard.2026.06.009_bib0036","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1093\/rheumatology\/kead025","article-title":"Quality standards for the care of people with giant cell arteritis in secondary care","volume":"62","author":"Coath","year":"2023","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.ard.2026.06.009_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2025.152793","article-title":"Impact of a rapid access strategy on referral rates, diagnosis, and glucocorticoid initiation in suspected polymyalgia rheumatica","volume":"74","author":"Nielsen","year":"2025","journal-title":"Semin Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.ard.2026.06.009_bib0038","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1136\/annrheumdis-2021-221126","article-title":"Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2\/3 randomised controlled trial","volume":"81","author":"Bonelli","year":"2022","journal-title":"Ann Rheum Dis."},{"issue":"11","key":"10.1016\/j.ard.2026.06.009_bib0039","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1001\/jama.2022.15459","article-title":"Effect of Tocilizumab on Disease Activity in Patients With Active Polymyalgia Rheumatica Receiving Glucocorticoid Therapy: A Randomized Clinical Trial","volume":"328","author":"Devauchelle-Pensec","year":"2022","journal-title":"JAMA."},{"issue":"14","key":"10.1016\/j.ard.2026.06.009_bib0040","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1056\/NEJMoa2303452","article-title":"Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper","volume":"389","author":"Spiera","year":"2023","journal-title":"N Engl J Med."},{"issue":"1","key":"10.1016\/j.ard.2026.06.009_bib0041","doi-asserted-by":"crossref","first-page":"rkz001","DOI":"10.1093\/rap\/rkz001","article-title":"Development of an evidence-based regimen of prednisolone to treat giant cell arteritis - the Norwich regimen","volume":"3","author":"Mukhtyar","year":"2019","journal-title":"Rheumatol Adv Pract."},{"issue":"5","key":"10.1016\/j.ard.2026.06.009_bib0042","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1093\/mr\/roab091","article-title":"Risk of adrenal insufficiency in patients with polymyalgia rheumatica versus patients with rheumatoid arthritis: A cross-sectional study","volume":"32","author":"Kasahara","year":"2022","journal-title":"Mod Rheumatol."},{"issue":"25","key":"10.1016\/j.ard.2026.06.009_bib0043","doi-asserted-by":"crossref","first-page":"e680","DOI":"10.1503\/cmaj.190178","article-title":"Incidence of infections associated with oral glucocorticoid dose in people diagnosed with polymyalgia rheumatica or giant cell arteritis: a cohort study in England","volume":"191","author":"Wu","year":"2019","journal-title":"Cmaj"},{"issue":"11","key":"10.1016\/j.ard.2026.06.009_bib0044","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1002\/art.42928","article-title":"Association of Cardiovascular Outcomes With Low-Dose Glucocorticoid Prescription in Patients With Rheumatoid Arthritis","volume":"76","author":"Coburn","year":"2024","journal-title":"Arthritis Rheumatol."},{"issue":"5","key":"10.1016\/j.ard.2026.06.009_bib0045","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1136\/annrheumdis-2019-216802","article-title":"Immunosuppression and the risk of readmission and mortality in patients with rheumatoid arthritis undergoing hip fracture, abdominopelvic and cardiac surgery","volume":"79","author":"George","year":"2020","journal-title":"Ann Rheum Dis."},{"issue":"4","key":"10.1016\/j.ard.2026.06.009_bib0046","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of Tocilizumab in Giant-Cell Arteritis","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ard.2026.06.009_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2025.152646","article-title":"An analysis of the first relapse in giant cell arteritis using ultrasonography","volume":"71","author":"Mukhtyar","year":"2025","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.ard.2026.06.009_bib0048","doi-asserted-by":"crossref","first-page":"rkaf050","DOI":"10.1093\/rap\/rkaf050","article-title":"Adrenal insufficiency in giant cell arteritis","volume":"9","author":"Ducker","year":"2025","journal-title":"Rheumatol Adv Pract."},{"issue":"9","key":"10.1016\/j.ard.2026.06.009_bib0049","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1093\/rheumatology\/kez630","article-title":"Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study","volume":"59","author":"Nakaoka","year":"2020","journal-title":"Rheumatology (Oxford)."},{"issue":"4","key":"10.1016\/j.ard.2026.06.009_bib0050","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.semarthrit.2020.04.003","article-title":"Assessment of damage in Takayasu's arteritis","volume":"50","author":"Kaymaz-Tahra","year":"2020","journal-title":"Semin Arthritis Rheum."},{"issue":"4","key":"10.1016\/j.ard.2026.06.009_bib0051","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1080\/03009740510026526","article-title":"Clinical characteristics and outcomes of Takayasu's arteritis: analysis of 108 patients using standardized criteria for diagnosis, activity assessment, and angiographic classification","volume":"34","author":"Park","year":"2005","journal-title":"Scand J Rheumatol."},{"issue":"2","key":"10.1016\/j.ard.2026.06.009_bib0052","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1093\/rheumatology\/keae333","article-title":"Assessment of damage in Takayasu's arteritis","volume":"64","author":"Kermani","year":"2025","journal-title":"Rheumatology (Oxford)."},{"issue":"2","key":"10.1016\/j.ard.2026.06.009_bib0053","doi-asserted-by":"crossref","first-page":"rkac034","DOI":"10.1093\/rap\/rkac034","article-title":"Long-term use of glucocorticoids for polymyalgia rheumatica: follow-up of the PMR Cohort Study","volume":"6","author":"Muller","year":"2022","journal-title":"Rheumatol Adv Pract."},{"issue":"2","key":"10.1016\/j.ard.2026.06.009_bib0054","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1080\/14397595.2020.1777680","article-title":"Predictors of long-term therapy with glucocorticoid in polymyalgia rheumatica","volume":"31","author":"Aoki","year":"2021","journal-title":"Mod Rheumatol."},{"issue":"8","key":"10.1016\/j.ard.2026.06.009_bib0055","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1136\/annrheumdis-2015-208742","article-title":"Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study","volume":"75","author":"Devauchelle-Pensec","year":"2016","journal-title":"Ann Rheum Dis."},{"issue":"12","key":"10.1016\/j.ard.2026.06.009_bib0056","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1111\/1756-185X.13723","article-title":"Tocilizumab monotherapy for polymyalgia rheumatica: A prospective, single-center, open-label study","volume":"22","author":"Chino","year":"2019","journal-title":"Int J Rheum Dis."},{"issue":"7S Suppl 2","key":"10.1016\/j.ard.2026.06.009_bib0057","doi-asserted-by":"crossref","first-page":"S213","DOI":"10.1097\/RHU.0000000000001414","article-title":"Usefulness of Methotrexate in the Reduction of Relapses and Recurrences in Polymyalgia Rheumatica: An Observational Study","volume":"26","author":"de la Torre","year":"2020","journal-title":"J Clin Rheumatol"},{"issue":"22","key":"10.1016\/j.ard.2026.06.009_bib0058","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1001\/jama.2016.5444","article-title":"Polymyalgia Rheumatica and Giant Cell Arteritis: A Systematic Review","volume":"315","author":"Buttgereit","year":"2016","journal-title":"JAMA."},{"issue":"1","key":"10.1016\/j.ard.2026.06.009_bib0059","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/ard-2022-223429","article-title":"Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica","volume":"83","author":"Dejaco","year":"2024","journal-title":"Ann Rheum Dis."},{"issue":"1","key":"10.1016\/j.ard.2026.06.009_bib0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2022.105494","article-title":"Epidemiology and predictors of relapse in giant cell arteritis: A systematic review and meta-analysis","volume":"90","author":"Moreel","year":"2023","journal-title":"Joint Bone Spine."},{"issue":"5","key":"10.1016\/j.ard.2026.06.009_bib0061","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/art.11388","article-title":"Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes","volume":"49","author":"Proven","year":"2003","journal-title":"Arthritis Rheum."},{"issue":"20","key":"10.1016\/j.ard.2026.06.009_bib0062","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1056\/NEJMoa2413449","article-title":"A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis","volume":"392","author":"Blockmans","year":"2025","journal-title":"N Engl J Med."},{"issue":"4","key":"10.1016\/j.ard.2026.06.009_bib0063","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/art.40044","article-title":"A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis","volume":"69","author":"Langford","year":"2017","journal-title":"Arthritis Rheumatol."},{"issue":"5","key":"10.1016\/j.ard.2026.06.009_bib0064","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1136\/annrheumdis-2021-221865","article-title":"Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"81","author":"Cid","year":"2022","journal-title":"Ann Rheum Dis."},{"issue":"6","key":"10.1016\/j.ard.2026.06.009_bib0065","doi-asserted-by":"crossref","first-page":"e341","DOI":"10.1016\/S2665-9913(23)00101-7","article-title":"Safety and efficacy of secukinumab in patients with giant cell arteritis (TitAIN): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"5","author":"Venhoff","year":"2023","journal-title":"Lancet Rheumatol."},{"issue":"8","key":"10.1016\/j.ard.2026.06.009_bib0066","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1002\/art.22754","article-title":"Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis","volume":"56","author":"Mahr","year":"2007","journal-title":"Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.ard.2026.06.009_bib0067","doi-asserted-by":"crossref","first-page":"106","DOI":"10.7326\/0003-4819-134-2-200101160-00010","article-title":"Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial","volume":"134","author":"Jover","year":"2001","journal-title":"Ann Intern Med."},{"issue":"5","key":"10.1016\/j.ard.2026.06.009_bib0068","first-page":"495","article-title":"A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA)","volume":"19","author":"Spiera","year":"2001","journal-title":"Clin Exp Rheumatol."},{"issue":"5","key":"10.1016\/j.ard.2026.06.009_bib0069","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/art.10262","article-title":"A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis","volume":"46","author":"Hoffman","year":"2002","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.ard.2026.06.009_bib0070","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13063-024-07905-4","article-title":"The Meteoritics Trial: efficacy of methotrexate after remission-induction with tocilizumab and glucocorticoids in giant cell arteritis-study protocol for a randomized, double-blind, placebo-controlled, parallel-group phase II study","volume":"25","author":"Kreis","year":"2024","journal-title":"Trials."},{"issue":"12","key":"10.1016\/j.ard.2026.06.009_bib0071","doi-asserted-by":"crossref","first-page":"e736","DOI":"10.1016\/S2665-9913(23)00265-5","article-title":"Treatment for giant cell arteritis with 8 weeks of prednisone in combination with tocilizumab: a single-arm, open-label, proof-of-concept study","volume":"5","author":"Unizony","year":"2023","journal-title":"Lancet Rheumatol."},{"issue":"9","key":"10.1016\/j.ard.2026.06.009_bib0072","doi-asserted-by":"crossref","first-page":"e619","DOI":"10.1016\/S2665-9913(21)00152-1","article-title":"Tocilizumab monotherapy after ultra-short glucocorticoid administration in giant cell arteritis: a single-arm, open-label, proof-of-concept study","volume":"3","author":"Christ","year":"2021","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.ard.2026.06.009_bib0073","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2024.152508","article-title":"Taper versus discontinuation of tocilizumab in patients with giant cell arteritis: Real-world experience from a tertiary center","volume":"68","author":"Nielsen","year":"2024","journal-title":"Semin Arthritis Rheum."},{"issue":"7","key":"10.1016\/j.ard.2026.06.009_bib0074","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1093\/rheumatology\/keab780","article-title":"New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension","volume":"61","author":"Stone","year":"2022","journal-title":"Rheumatology (Oxford)."},{"issue":"12","key":"10.1016\/j.ard.2026.06.009_bib0075","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1093\/rheumatology\/kead604","article-title":"Relapse after cessation of weekly tocilizumab for giant cell arteritis: a multicentre service evaluation in England","volume":"63","author":"Quick","year":"2024","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.ard.2026.06.009_bib0076","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2023.152174","article-title":"Effectiveness of a two-year tapered course of tocilizumab in patients with giant cell arteritis: A single-centre prospective study","volume":"59","author":"Tomelleri","year":"2023","journal-title":"Semin Arthritis Rheum."},{"issue":"5","key":"10.1016\/j.ard.2026.06.009_bib0077","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1093\/rheumatology\/kead387","article-title":"Treatment efficacy and safety of adalimumab versus tocilizumab in patients with active and severe Takayasu arteritis: an open-label study","volume":"63","author":"Wang","year":"2024","journal-title":"Rheumatology (Oxford)."},{"issue":"3","key":"10.1016\/j.ard.2026.06.009_bib0078","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103275","article-title":"The effectiveness of tocilizumab and its comparison with tumor necrosis factor alpha inhibitors for Takayasu Arteritis: A systematic review and meta-analysis","volume":"22","author":"Misra","year":"2023","journal-title":"Autoimmun Rev."},{"key":"10.1016\/j.ard.2026.06.009_bib0079","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2025.152814","article-title":"Concordance of relapse symptoms in patients with giant cell arteritis","volume":"74","author":"Guarda","year":"2025","journal-title":"Semin Arthritis Rheum."},{"issue":"11","key":"10.1016\/j.ard.2026.06.009_bib0080","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.3899\/jrheum.121473","article-title":"New features of disease after diagnosis in 6 forms of systemic vasculitis","volume":"40","author":"Grayson","year":"2013","journal-title":"J Rheumatol."},{"key":"10.1016\/j.ard.2026.06.009_bib0081","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1016\/S0167-5273(96)88778-X","article-title":"Takayasu arteritis: lessons from the American National Institutes of Health experience","volume":"54 Suppl","author":"Hoffman","year":"1996","journal-title":"Int J Cardiol."},{"issue":"4","key":"10.1016\/j.ard.2026.06.009_bib0082","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1093\/rheumatology\/14.4.231","article-title":"Polymyalgia rheumatica and giant cell arteritis: a seven-year survey","volume":"14","author":"Myles","year":"1975","journal-title":"Rheumatol Rehabil."},{"issue":"2","key":"10.1016\/j.ard.2026.06.009_bib0083","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/rheumatology\/ken343","article-title":"Polymyalgia rheumatica can be distinguished from late onset rheumatoid arthritis at baseline: results of a 5-yr prospective study","volume":"48","author":"Pease","year":"2009","journal-title":"Rheumatology (Oxford)."},{"issue":"10","key":"10.1016\/j.ard.2026.06.009_bib0084","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1136\/annrheumdis-2013-203465","article-title":"Is cancer associated with polymyalgia rheumatica? A cohort study in the General Practice Research Database","volume":"73","author":"Muller","year":"2014","journal-title":"Ann Rheum Dis."},{"issue":"4","key":"10.1016\/j.ard.2026.06.009_bib0085","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1177\/096721099400200415","article-title":"Focal occlusive disease of the common femoral artery: a report of 20 cases","volume":"2","author":"Mandalam","year":"1994","journal-title":"Cardiovasc Surg."},{"issue":"1","key":"10.1016\/j.ard.2026.06.009_bib0086","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003775","article-title":"Reappraisal of large artery involvement in giant cell arteritis: a population-based cohort over 70 years","volume":"10","author":"Elfishawi","year":"2024","journal-title":"RMD Open."},{"issue":"11","key":"10.1016\/j.ard.2026.06.009_bib0087","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1002\/acr.24055","article-title":"Patterns of arterial disease in Takayasu arteritis and giant cell arteritis","volume":"72","author":"Gribbons","year":"2020","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"1","key":"10.1016\/j.ard.2026.06.009_bib0088","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvs.2021.06.479","article-title":"Surgical strategy for inflammatory thoracic aortic aneurysms in the endovascular surgery era","volume":"75","author":"Oishi","year":"2022","journal-title":"J Vasc Surg."},{"issue":"3","key":"10.1016\/j.ard.2026.06.009_bib0089","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1080\/08941939.2017.1408718","article-title":"Treatment with corticosteroid and\/or immunosuppressive agents before surgery can effectively improve the surgical outcome in patients with Takayasu's arteritis","volume":"32","author":"Zheng","year":"2019","journal-title":"J Invest Surg."},{"key":"10.1016\/j.ard.2026.06.009_bib0090","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.avsg.2019.07.009","article-title":"Surgery and endovascular management in patients With Takayasu's arteritis: a ten-year retrospective study","volume":"63","author":"Diao","year":"2020","journal-title":"Ann Vasc Surg."},{"issue":"6","key":"10.1016\/j.ard.2026.06.009_bib0091","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1161\/CIRCULATIONAHA.111.058032","article-title":"Retrospective analysis of surgery versus endovascular intervention in Takayasu arteritis: a multicenter experience","volume":"125","author":"Saadoun","year":"2012","journal-title":"Circulation."},{"issue":"12","key":"10.1016\/j.ard.2026.06.009_bib0092","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.3899\/jrheum.140124","article-title":"Hospitalized infections in giant cell arteritis: a population-based retrospective cohort study","volume":"41","author":"Udayakumar","year":"2014","journal-title":"J Rheumatol."},{"issue":"2","key":"10.1016\/j.ard.2026.06.009_bib0093","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/rheumatology\/keae107","article-title":"The one-year infection risk among patients diagnosed with giant cell arteritis: use of antibiotics and hospitalisations","volume":"64","author":"Therkildsen","year":"2025","journal-title":"Rheumatology (Oxford)."},{"issue":"2","key":"10.1016\/j.ard.2026.06.009_bib0094","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/rheumatology\/keae098","article-title":"Follow-up ultrasound examination in patients with newly diagnosed giant cell arteritis","volume":"64","author":"Sch\u00e4fer","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2026.06.009_bib0095","article-title":"Aortic disease in giant cell arteritis","volume":"72S","author":"Warrington","year":"2025","journal-title":"Semin Arthritis Rheum."},{"issue":"12","key":"10.1016\/j.ard.2026.06.009_bib0096","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1093\/rheumatology\/kead584","article-title":"Increased mortality rate in Takayasu arteritis is largely driven by cardiovascular disease: a cohort study","volume":"63","author":"Jagtap","year":"2024","journal-title":"Rheumatology (Oxford)."},{"issue":"3","key":"10.1016\/j.ard.2026.06.009_bib0097","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003481","article-title":"Cardiovascular diseases and their associations with lipid parameters and endothelial dysfunction in giant cell arteritis","volume":"9","author":"Jud","year":"2023","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.ard.2026.06.009_bib0098","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s10067-023-06829-9","article-title":"Renal artery involvement is associated with increased morbidity but not mortality in Takayasu arteritis: a matched cohort study of 215 patients","volume":"43","author":"Thakare","year":"2024","journal-title":"Clin Rheumatol."},{"issue":"10","key":"10.1016\/j.ard.2026.06.009_bib0099","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1093\/jbmr\/zjaf091","article-title":"Body mass index and subsequent fracture risk: a meta-analysis to update FRAX","volume":"40","author":"Harvey","year":"2025","journal-title":"J Bone Miner Res."}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726003572?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726003572?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T05:40:44Z","timestamp":1786081244000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496726003572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":99,"alternative-id":["S0003496726003572"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2026.06.009","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"2025 EULAR recommendations for the management of polymyalgia rheumatica and primary large vessel vasculitis","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2026.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}